Trials

Cancer type Title Status Country
Breast cancer A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con Inclusion completed SE
Breast cancer A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to An-astrozole alone, in Post menopausal Women With Hormone Receptor positive, Endocrine T Inclusion completed FI
Breast cancer A prospective phase II study to evaluate alternations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression efter initial exposure to trastuzumab-taxane based treatment Inclusion completed SE
Breast cancer A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation Open for inclusion NO
Breast cancer First in human study in HER2 positive primary breast cancer patient who are eligible for neoadjuvant chemotherapy Open for inclusion DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver mestastases from breast cancer. Only patients without extrahepatic disease are included Open for inclusion DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease Open for inclusion DK
Breast cancer Phase Ib, Open-Label, Multicenter, Doseescalation Study followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of Ro5479599, a Glycoengineered Antibody Against Her3, Administered in combination with Pertuzumab and Paclitaxel Open for inclusion DK
Breast cancer Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer Open for inclusion SE
Breast cancer Randomized phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with pro-gressive brain metastases after trastuzumab or lapatinib based therapy Inclusion completed FI
Cholangiocarcinoma A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma Open for inclusion DK
Colorectal cancer A double blinded randomised three armed phase II trial of PledOx in two different doses in combination with FOLFOX6 compared to placebo + FOLFOX6 in patients with advanced metastatic colorectal (stage IV) cancer Open for inclusion SE
Colorectal cancer A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer Open for inclusion NO
Colorectal cancer Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer Inclusion completed SE
Colorectal cancer Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours Open for inclusion DK
Colorectal cancer Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer Open for inclusion FI
Colorectal cancer Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial Open for inclusion NO
Colorectal cancer Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial Inclusion completed FI
Colorectal cancer The international liver tumor group. Radiofrequency ablation versus stereotactic body radiation therapy for colorectal liver metastases: A randomized trial Open for inclusion SE
Esophageal cancer Follow up of Phase I study of radiotherapy and platinum-Fluouracil based chemotherapy with cetuximab in locally advanced esopgael cancer Open for inclusion DK
Gastric cancer Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group Open for inclusion FI
Gastric cancer Phase I-II study of traztuzumab combined with docetaxel, oxaliplatin and capecitabine in advanced or metastatic gastic or cardia cancer Open for inclusion DK
Glioblastoma BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) Inclusion completed DK
Glioblastoma DC-CAST-GBM Inclusion completed NO
Glioblastoma Electrochemotherapy as a Palliative Treatment for Brain Metastases Open for inclusion DK
Glioblastoma Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM Inclusion completed DK
Head and Neck cancer A multicentre, open label, randomised phase II study with or without induction chemotherapy, combined with radiotherapy and cetuximab (Erbitux®®) in locally advanced unresectable squamous cell carcinoma of the head & neck with HPV positive tumors Open for inclusion SE
Head and Neck cancer A Phase 1b/2 study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer Open for inclusion SE
Head and Neck cancer An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment. Open for inclusion SE
Head and Neck cancer Boron neutron capture therapy (BNCT) for the treatment of inoperable head and neck cancer Inclusion completed FI
Hematological malignancies A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies Open for inclusion DK
Leukemia A multicenter open randomised phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) Open for inclusion DK
Leukemia A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q Open for inclusion NO
Leukemia A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia Open for inclusion NO
Leukemia A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. Open for inclusion NO
Leukemia A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia Open for inclusion DK
Leukemia A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia Open for inclusion NO
Lung cancer A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment Open for inclusion NO
Lung cancer A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment Open for inclusion NO
Lung cancer A phase I/IIa study of UV1 vaccination in patients with non-small cell lung cancer Open for inclusion NO
Lung cancer A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer Open for inclusion NO
Lung cancer CAUY922A2206 NSCLC Inclusion completed NO
Lung cancer IDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients Open for inclusion DK
Lung cancer Open randomized phase-II trial of SBRT + chemotherapy vs chemotherapy in NSCLC patients with a maximum of 5 tumor lesions Open for inclusion SE
Lung cancer Phase I and II studies of intravenous sodium SElenite as a cytotoxic agent in advanced CARcinoma of the lung Open for inclusion SE
Lung cancer Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma Open for inclusion NO
Lung cancer Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma Open for inclusion NO
Lung cancer Phase II randomized study on Locally Advanced Non small cell lung cancer. Escalated dose on individual basis, treatment with radiochemotherapy Open for inclusion SE
Lymphoma A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement Inclusion completed FI
Lymphoma Chemo-immunotherapy with early central nervous system (CNS) prophylaxis Open for inclusion DK
Lymphoma Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) Open for inclusion FI
Lymphoma Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi Inclusion completed FI
Lymphoma Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL) Open for inclusion DK
Lymphoma Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas Open for inclusion FI
Lymphoma Randomised phase II trial on primary chemotherapy with high-dose methtrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell trans Open for inclusion DK
Lymphoma Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial Open for inclusion SE
Lymphoma, Sarcoma Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET Open for inclusion NO
Melanoma A phase 1 study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma Open for inclusion SE
Melanoma A randomised Phase II study of MK-3475 versus Chemotherapy in Pateients with Advanced Melanoma Inclusion completed NO
Melanoma A single arm, open-label, phase II, multicentre study, to assess the safety of vismodegib(GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC) Open for inclusion SE
Melanoma CA184025 Malign melanoma (inop. III and IV) Inclusion completed NO
Melanoma CLGX818X2101 Locally advanced or mestastatic BRAF mutant melanoma Inclusion completed NO
Melanoma DC-004 Unresectable metastases (Stage III or IV M1a-c-Malign melanoma) Inclusion completed NO
Melanoma Safety and efficacy of intratumoural electrotransfer of Plasmid AMEP in patients suffering from advanced or metastatic melanoma: an open phase 1 trial Open for inclusion DK
Melanoma T-cell therapy for patients with malignant melanoma Open for inclusion DK
Melanoma The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients) Open for inclusion FI
Melanoma Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Open for inclusion DK
Multiple diagnosis A phase I, open‐label, multi‐centre, multi‐dose, dose escalation study of LTX‐315 in patients with transdermally accessible tumours Open for inclusion NO
Multiple diagnosis A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib Open for inclusion NO
Multiple diagnosis C08-315-01 Transdermally accessible tumour Inclusion completed NO
Multiple diagnosis Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours Open for inclusion DK
Multiple diagnosis MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma Inclusion completed NO
Multiple diagnosis Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer Inclusion completed NO
Myeloma A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma Inclusion completed DK
Myeloma Daratumumab (anti-CD38) in refractory multiple myeloma, first in humans Open for inclusion DK
Myeloma Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma Open for inclusion DK
Oesophagus A phase II study with Oxaliplatin + 5-Fu + Cetuximab and radiotherapy for the treatment of non-resectable, locally advanced but not metastatic cancer of oesophagus or the cardia Open for inclusion SE
Ovarian cancer A phase II non comparative study with paclitaxel and carboplatin in combination with vorinostat in patients with advanced recurrent epithelia ovarian carcinoma Open for inclusion DK
Ovarian cancer DC-006 Recurrent ovarian epithelial cancer Open for inclusion NO
Pancreatic cancer A Phase I/II Trial and TG01 Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas Open for inclusion NO
Pancreatic cancer Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) Inclusion completed NO
Pancreatic cancer Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Inclusion completed SE
Pancreatic cancer Safety, pharmacokinetics and efficacy of AXP107-11 in patients with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the pancreas, stage III-IV. Open for inclusion SE
Pancreatic cancer Treatment of pancreatic adenocarcinoma by combining contrast agent and gemcitabine under sonication. Open for inclusion NO
Prostate cancer A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer Inclusion completed FI
Prostate cancer A phase I/IIa study of UV1 vaccination in patients with hormone-sensitive metastatic prostate cancer Open for inclusion NO
Prostate cancer A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (ConCab) Open for inclusion SE
Prostate cancer DC-005 Prostate Open for inclusion NO
Prostate cancer Dendritic cell vaccination in combination with Docetaxel for patients with prostate cancer – a randomized phase II study Open for inclusion DK
Prostate cancer Open, single-arm, multicenter, phase II trial investigating the safety of biweekly cabazi-taxel in metastatic castration resistant prostate cancer patients previously treated with docetaxel-containing regimen Inclusion completed FI
Prostate cancer Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component Inclusion completed FI
Sarcoma A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall Open for inclusion SE
Sarcoma Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group Open for inclusion NO
Skin cancer Combined treatment with Autologous Dendritic cells and T cells in patients with advanced Melanoma Open for inclusion SE
Solide tumores A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function Inclusion completed SE
Solide tumores A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies Open for inclusion DK
Solide tumores A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on dovitinib (TKI258) pharmacokinetics in patients with advanced solid tumors Open for inclusion DK
Solide tumores A phase I, open-label study to evaluate the PK and safety of panobinostat in patients with advanced solid tumors and varying degrees of renal function Open for inclusion SE
Solide tumores A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors Open for inclusion FI
Solide tumores A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors Open for inclusion DK
Solide tumores An open non-randomized study to investigate the local tumour control rate in patients with centrally located lung lesions who receive treatment with Stereotactic body radiotherapy Open for inclusion SE
Solide tumores An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic Open for inclusion FI
Solide tumores CMEK162X2102 All solid tumors with BRAF or RAF mutation Inclusion completed NO
Solide tumores First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors Inclusion completed DK
Solide tumores Phase I dose-escalating study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours Open for inclusion DK
Solide tumores Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer Inclusion completed DK
Solide tumores TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study Inclusion completed DK
Urothelial A phase II open label, single arm study evaluating treatment with pazopanib post sunitinib treatment in patients with mRCC. Open for inclusion SE
Urothelial An exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Open for inclusion SE